Literature DB >> 25661443

c-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia.

Claire M Lucas1, Robert J Harris1, Athina Giannoudis1, Richard E Clark2.   

Abstract

Entities:  

Keywords:  10058-F4; CIP2A; CML; MYC; PP2A

Mesh：

Substances：

Year:  2015        PMID： 25661443      PMCID： PMC4420226          DOI： 10.3324/haematol.2014.115691

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

1.  The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein.

Authors:  Paolo Neviani; Ramasamy Santhanam; Rossana Trotta; Mario Notari; Bradley W Blaser; Shujun Liu; Hsiaoyin Mao; Ji Suk Chang; Annamaria Galietta; Ashwin Uttam; Denis C Roy; Mauro Valtieri; Rebecca Bruner-Klisovic; Michael A Caligiuri; Clara D Bloomfield; Guido Marcucci; Danilo Perrotti
Journal:  Cancer Cell       Date:  2005-11       Impact factor: 31.743

Review 2.  The ever expanding role for c-Myc in promoting genomic instability.

Authors:  Edward V Prochownik; Youjun Li
Journal:  Cell Cycle       Date:  2007-05-19       Impact factor: 4.534

3.  A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials.

Authors:  C M Lucas; L Wang; G M Austin; K Knight; S J Watmough; K H Shwe; R Dasgupta; Nauman M Butt; D Galvani; C F Hoyle; J R C Seale; R E Clark
Journal:  Leukemia       Date:  2008-08-28       Impact factor: 11.528

4.  [Expression of Bcl-2 protein and the amplification of c-myc gene in patients with chronic myeloid leukemia].

Authors:  Milica Strnad; Goran Brajusković; Natasa Strelić; Biljana Todorić Zivanović; Ljiljana Tukić; Dragana Stamatović
Journal:  Vojnosanit Pregl       Date:  2006-04       Impact factor: 0.168

5.  Detection of trisomy 8 in philadelphia chromosome-positive CML patients using conventional cytogenetic and interphase fluorescence in situ hybridization techniques and its relation to c-myc involvement.

Authors:  R Oudat; Z Khan; A B Glassman
Journal:  Ann Clin Lab Sci       Date:  2001-01       Impact factor: 1.256

6.  Dominant negative MYC blocks transformation by ABL oncogenes.

Authors:  C L Sawyers; W Callahan; O N Witte
Journal:  Cell       Date:  1992-09-18       Impact factor: 41.582

7.  The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene.

Authors:  Y Ben-Neriah; G Q Daley; A M Mes-Masson; O N Witte; D Baltimore
Journal:  Science       Date:  1986-07-11       Impact factor: 47.728

8.  Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.

Authors:  Hugues de Lavallade; Jane F Apperley; Jamshid S Khorashad; Dragana Milojkovic; Alistair G Reid; Marco Bua; Richard Szydlo; Eduardo Olavarria; Jaspal Kaeda; John M Goldman; David Marin
Journal:  J Clin Oncol       Date:  2008-06-02       Impact factor: 44.544

9.  CIP2A inhibits PP2A in human malignancies.

Authors:  Melissa R Junttila; Pietri Puustinen; Minna Niemelä; Raija Ahola; Hugh Arnold; Trine Böttzauw; Risto Ala-aho; Christina Nielsen; Johanna Ivaska; Yoichi Taya; Shi-Long Lu; Shujun Lin; Edward K L Chan; Xiao-Jing Wang; Reidar Grènman; Juergen Kast; Tuula Kallunki; Rosalie Sears; Veli-Matti Kähäri; Jukka Westermarck
Journal:  Cell       Date:  2007-07-13       Impact factor: 41.582

10.  Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression.

Authors:  Claire M Lucas; Robert J Harris; Athina Giannoudis; Mhairi Copland; Joseph R Slupsky; Richard E Clark
Journal:  Blood       Date:  2011-04-13       Impact factor: 22.113
View more
  9 in total

1.  CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML.

Authors:  Claire M Lucas; Laura J Scott; Natasha Carmell; Alison K Holcroft; Robert K Hills; Alan K Burnett; Richard E Clark
Journal:  Blood Adv       Date:  2018-05-08

2.  Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients.

Authors:  C M Lucas; R J Harris; A K Holcroft; L J Scott; N Carmell; E McDonald; F Polydoros; R E Clark
Journal:  Leukemia       Date:  2015-03-13       Impact factor: 11.528

3.  BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene.

Authors:  Nitesh Sharma; Vera Magistroni; Rocco Piazza; Stefania Citterio; Caterina Mezzatesta; Praveen Khandelwal; Alessandra Pirola; Carlo Gambacorti-Passerini
Journal:  Mol Cancer       Date:  2015-07-16       Impact factor: 27.401

4.  Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia.

Authors:  Nameeta P Richard; Raffaella Pippa; Megan M Cleary; Alka Puri; Deanne Tibbitts; Shawn Mahmood; Dale J Christensen; Sophia Jeng; Shannon McWeeney; A Thomas Look; Bill H Chang; Jeffrey W Tyner; Michael P Vitek; María D Odero; Rosalie Sears; Anupriya Agarwal
Journal:  Oncotarget       Date:  2016-12-20

Review 5.  Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.

Authors:  Yammy Yung; Emily Lee; Hiu-Tung Chu; Pui-Kwan Yip; Harinder Gill
Journal:  Int J Mol Sci       Date:  2021-01-11       Impact factor: 5.923

6.  Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia.

Authors:  Richard E Clark; Ammar A Basabrain; Gemma M Austin; Alison K Holcroft; Sandra Loaiza; Jane F Apperley; Christopher Law; Laura Scott; Alexandra D Parry; Laura Bonnett; Claire M Lucas
Journal:  Cancers (Basel)       Date:  2021-04-29       Impact factor: 6.639

7.  High CIP2A levels correlate with an antiapoptotic phenotype that can be overcome by targeting BCL-XL in chronic myeloid leukemia.

Authors:  C M Lucas; M Milani; M Butterworth; N Carmell; L J Scott; R E Clark; G M Cohen; S Varadarajan
Journal:  Leukemia       Date:  2016-02-29       Impact factor: 11.528

8.  A Novel Naphthoquinone-Coumarin Hybrid That Inhibits BCR-ABL1-STAT5 Oncogenic Pathway and Reduces Survival in Imatinib-Resistant Chronic Myelogenous Leukemia Cells.

Authors:  Patricia Martín-Rodríguez; Borja Guerra; Idaira Hueso-Falcón; Haidee Aranda-Tavío; Juan Díaz-Chico; José Quintana; Francisco Estévez; Bonifacio Díaz-Chico; Angel Amesty; Ana Estévez-Braun; Leandro Fernández-Pérez
Journal:  Front Pharmacol       Date:  2019-01-09       Impact factor: 5.810

Review 9.  The Role of MYC and PP2A in the Initiation and Progression of Myeloid Leukemias.

Authors:  Raffaella Pippa; Maria D Odero
Journal:  Cells       Date:  2020-02-26       Impact factor: 6.600
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.